Lactobacillus for Diarrhea Management

Evidence-Based Indications for Lactobacillus

The American Gastroenterological Association recommends Lactobacillus rhamnosus at 5-10 billion CFU/day for preventing antibiotic-associated diarrhea, with low probability of adverse events 1, 3, 4
Probiotics reduce the risk of developing Clostridium difficile-associated diarrhea by 64% when given with antibiotics, representing both safe and effective prevention 1, 2, 3, 4
The incidence of Clostridium difficile-associated diarrhea drops from 5.5% in controls to 2.0% with probiotics (RR 0.36; 95% CI 0.26-0.51) 3, 4
Benefit is primarily seen in high-risk populations with >15% baseline risk, including elderly (>65 years), prolonged hospitalization, severe underlying illness, or previous C. difficile infection 5
The World Health Organization suggests that probiotics should not be used in immunocompromised patients due to risk of bacteremia or fungemia, including neutropenic patients, severely debilitated patients, patients with central venous catheters, and those with severe underlying illness 7, 4, 5

Lactobacillus rhamnosus: 5-10 billion CFU/day is recommended by the European Society of Clinical Microbiology and Infectious Diseases for preventing antibiotic-associated diarrhea 1, 3, 4
Saccharomyces boulardii: 1g or 3×10¹⁰ CFU/day is recommended by the Infectious Diseases Society of America, with a 59% risk reduction 5, 6

The Centers for Disease Control and Prevention advise against using probiotics in immunocompromised patients due to risk of bacteremia or fungemia 7, 5, 6

The American College of Gastroenterology recommends assessing immune status and identifying high-risk patients (elderly, hospitalized, previous CDI) for probiotic use, and starting Lactobacillus rhamnosus or Saccharomyces boulardii at antibiotic initiation 5, 6
The Society for Healthcare Epidemiology of America suggests continuing probiotics throughout antibiotic course plus 1-2 weeks after 5, 6

The National Institutes of Health note that strain specificity is critical, and benefits demonstrated for one strain cannot be extrapolated to others 8, 5, 6
The European Food Safety Authority states that evidence quality is rated as low to moderate due to heterogeneity in study populations and probiotic strains 5, 6
The American Academy of Pediatrics reports that adverse events are rare and include mild gastrointestinal symptoms (abdominal cramping, flatulence, nausea) 3, 4